A Phase I/IIa trial of a frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers.

CONCLUSIONS: FSP neoantigen vaccination is systemically well tolerated and consistently induces humoral and cellular immune responses, thus representing a promising novel approach for treatment and even prevention of MMR-deficient cancer.
PMID: 32540851 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - June 14, 2020 Category: Cancer & Oncology Authors: Kloor M, Reuschenbach M, Pauligk C, Karbach J, Rafiyan MR, Al-Batran SE, Tariverdian M, Jaeger E, von Knebel Doeberitz M Tags: Clin Cancer Res Source Type: research